Nektar

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Friday, March 22, 2024
SAN, Conference, Q&A, NKTR, Nektar Therapeutics, Therapy, Nektar

SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.

Key Points: 
  • SAN FRANCISCO, March 22, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
  • The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until April 28, 2024.

Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Cornell University, Therapy, Acquisition, Nektar, Senior, Woman of the Year, American City Business Journals, Immunotherapy, Disassembler, Assembly, Nektar Therapeutics, Bristol Myers Squibb, Entrepreneurship, Radioimmunotherapy, University, Self-assembly, Woman, Cancer, Medical device

to the Company’s Board of Directors, effective February 29, 2024.

Key Points: 
  • to the Company’s Board of Directors, effective February 29, 2024.
  • Dr. Tagliaferri brings nearly 30 years of biopharmaceutical industry experience and oncology therapeutic development expertise to the Y-mAbs Board of Directors.
  • “We are thrilled to welcome Mary to our Board of Directors during such an exciting time for Y-mAbs,” said Michael Rossi, President and Chief Executive Officer.
  • Nektar is a clinical-stage, research-based drug discovery biopharmaceutical company focuses on discovering and developing innovative medicines in the field of immunotherapy.

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
SAN, Nektar, Q&A, Therapy, NKTR, Nektar Therapeutics, Conference

SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.

Key Points: 
  • SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time.
  • The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events .
  • This webcast will be available for replay until April 5, 2024.

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

Retrieved on: 
Monday, February 26, 2024
SAN, Home page, Nektar, Therapy, NKTR, PIN, Nektar Therapeutics

SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, Feb. 26, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2023 on Monday, March 4, 2024, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through April 4, 2024.
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.

Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer

Retrieved on: 
Monday, November 13, 2023
Natural science, University, Genetics, Research, Senior, Therapy, Nektar Therapeutics, Biotechnology, Pain management, Genomics, Chiron Corporation, Molecular biology, Genome, Nektar, Drug discovery, San Francisco Bay Area, Doctor of Philosophy, Amgen, Pharmaceutical industry, Management

Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.

Key Points: 
  • Oxford, UK, 13 November 2023 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company decoding the dark matter of the human genome for translational medicine, today announces the appointment of Dr Stephen Harrison as Chief Scientific Officer, effective immediately.
  • Prior to joining Nucleome, Dr Harrison held executive leadership positions at several biotechnology companies in the San Francisco Bay Area.
  • Most recently, he served as Chief Scientific Officer at Engine Biosciences, building and leading a team focused on functional genomics and machine learning-led target and drug discovery.
  • Dr Danuta Jeziorska, Chief Executive Officer and Founder of Nucleome, commented: “Steve has an outstanding track record in accelerated drug discovery and development across multiple therapeutic areas and innovative technologies.

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

Retrieved on: 
Tuesday, October 31, 2023
Nektar, Home page, Nektar Therapeutics, Therapy, NKTR, PIN, SAN, Cryptocurrency

SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.

Key Points: 
  • SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-based financial markets.
  • Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
  • The web broadcast of the conference call will be available for replay through December 8, 2023.
  • All registrants will receive dial-in information and a PIN allowing them to access the live call.

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Retrieved on: 
Monday, October 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Genentech, LLP, Drug development, Abstract, Harvard University, Pfizer, Data management, Drug, Pharmacyclics, Arena Pharmaceuticals, Therapy, SMMT, Quality of life, Lasso, PwC, Knowledge, Amgen, Biogen, AbbVie, Athenahealth, CFO, Stonehill College, Faculty, Risk, Jazz Pharmaceuticals, University, Cancer, Jazz, Trust, Nektar, Immunotherapy, CMO, Biostatistics, Information technology, Alnylam Pharmaceuticals, MD Anderson Cancer Center, Public health, Regulatory affairs, Nektar Therapeutics, Sale, Senior, Doctor of Philosophy, Licensed practical nurse, ARIAD Pharmaceuticals, Growth, Hematology, Patient, Management, Nursing, Pharmacovigilance, Robert Maki

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.
  • “Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit.
  • “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.
  • I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”
    Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer.

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

Retrieved on: 
Friday, October 13, 2023
Congress, Senior, NKTR, Alopecia areata, European Academy of Management, George Washington University School of Engineering and Applied Science, Development, Journal of the European Academy of Dermatology and Venereology, DLQI, Atopic dermatitis, Outline of health sciences, Contact dermatitis, Nektar, Psoriasis Area and Severity Index, Pharmacodynamics, Maintenance, SAN, AD, EASI, BSA, Patient, NRS, Nektar Therapeutics, Body surface area, Pharmaceutical industry, Regulatory T cell, Dermatology, Venereology

SAN FRANCISCO, Oct. 13, 2023  /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, in patients with atopic dermatitis (AD) at the 2023 European Academy of Dermatology and Venereology (EADV) Congress. These data were presented by Dr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Director of Clinical Research and Contact Dermatitis in a late-breaking oral presentation.

Key Points: 
  • "Data from this presentation demonstrate consistent benefit with REZPEG across multiple clinician and patient-reported outcomes, which were maintained through 36 weeks after treatment ended," said Dr. Jonathan Silverberg.
  • "The sustained post-treatment benefit observed with REZPEG has the potential to alter the need for frequent maintenance dosing for patients with atopic dermatitis.
  • Based on these data, the company is initiating two Phase 2 studies in atopic dermatitis and in alopecia areata.
  • Highlight of the new patient-reported outcomes for the Phase 1b study in atopic dermatitis presented at EADV 2023 for the first time:

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

Retrieved on: 
Monday, October 2, 2023
Nektar, Medical school, Naval Medical Research Center, University, Senior, NKTR, Safety, Efficacy, University School, Nektar Therapeutics, MT, Atopic dermatitis, Washington University School of Medicine, Alopecia areata, University of Washington School of Medicine, Development, Journal of the European Academy of Dermatology and Venereology, Duke University School of Medicine, Patient, SAN, Randomness, Conjugation, University of Rochester Medical Center, Science, University of Bonn, Therapy, Abstract, Queen's University, Treatment, Education, Pharmaceutical industry, Vaccine, PLLC, Dermatology, Regulatory T cell, Venereology, Northwestern University, Medicine

SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin. REZPEG is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.

Key Points: 
  • SAN FRANCISCO, Oct. 2, 2023 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg) therapy, at the 2023 European Academy of Dermatology and Venereology (EADV) Congress to be held October 11-14 in Berlin.
  • REZPEG is in Phase 2 development for the treatment of atopic dermatitis and for the treatment of alopecia areata.
  • "The presentations highlight the momentum and strength of our REZPEG program and, in particular, its potential as a remittive therapy for patients with atopic dermatitis.
  • Sinai, New York, NY, United States; 6Skin Sciences, PLLC, Louisville, KY, United States; 7Rodgers Dermatology, Frisco, TX, United States; 8Nektar Therapeutics, San Francisco, CA, United States; 9Eli Lilly and Company, Indianapolis, IN, United States.

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

Retrieved on: 
Friday, September 15, 2023
Translation, University of California, San Diego Performance-Based Skills Assessment, Gilead Sciences, Nektar, Biotechnology, University, Therapy, Biochemistry, Senior, Nektar Therapeutics, Bachelor of Arts, ICON, Inflammation, Genentech, Trial of the century, Gilead, Fibrosis, Patient, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.
  • “Minnie is an accomplished biopharmaceutical leader who brings extensive clinical development and cross-functional portfolio management experience to Pliant,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer at Pliant.
  • Prior to joining Pliant, Ms. Kuo held roles of increasing responsibilities at Vir Biotechnology, most recently serving as Senior Vice President of Translational and Clinical Development Operations.
  • In this role, Ms. Kuo served as the operational officer to the Chief Medical Officer, overseeing business operations, clinical operations, and organizational planning across the entire clinical portfolio.